Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Milestone Pharmaceuticals Inc (MIST)

Milestone Pharmaceuticals Inc (MIST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 177,152
  • Shares Outstanding, K 85,169
  • Annual Sales, $ 0 K
  • Annual Income, $ -41,520 K
  • EBIT $ -57 M
  • EBITDA $ -57 M
  • 60-Month Beta 0.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.58

Options Overview Details

View History
  • Implied Volatility 162.61% (+28.71%)
  • Historical Volatility 92.86%
  • IV Percentile 30%
  • IV Rank 14.86%
  • IV High 645.74% on 04/03/25
  • IV Low 78.27% on 08/06/25
  • Expected Move (DTE 20) 0.35 (16.75%)
  • Put/Call Vol Ratio 0.86
  • Today's Volume 2,225
  • Volume Avg (30-Day) 7,300
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 38,136
  • Open Int (30-Day) 54,323
  • Expected Range 1.73 to 2.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.18
  • Number of Estimates 3
  • High Estimate -0.16
  • Low Estimate -0.21
  • Prior Year -0.19
  • Growth Rate Est. (year over year) +5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.61 +29.19%
on 12/12/25
3.06 -32.03%
on 12/12/25
-0.53 (-20.31%)
since 11/26/25
3-Month
1.61 +29.19%
on 12/12/25
3.06 -32.03%
on 12/12/25
+0.08 (+4.00%)
since 09/26/25
52-Week
0.63 +230.16%
on 04/09/25
3.06 -32.03%
on 12/12/25
+0.10 (+5.05%)
since 12/26/24

Most Recent Stories

More News
Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

Novel treatment for PSVT developed with Milestone Pharmaceuticals

MIST : 2.08 (+0.48%)
ATR : 123.25 (+0.41%)
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT  Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT...

MIST : 2.08 (+0.48%)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards,...

MIST : 2.08 (+0.48%)
Milestone Pharmaceuticals: Q3 Earnings Snapshot

Milestone Pharmaceuticals: Q3 Earnings Snapshot

MIST : 2.08 (+0.48%)
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

PDUFA Target Date of December 13, 2025 for CARDAMYST™ (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT) Promotional Launch Plans Set with Quick-Start Capability Upon Potential...

MIST : 2.08 (+0.48%)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards,...

MIST : 2.08 (+0.48%)
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

MONTREAL and CHARLOTTE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc . (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization...

MIST : 2.08 (+0.48%)
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

MONTREAL and CHARLOTTE, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 2.08 (+0.48%)
Milestone® Pharmaceuticals to Present at Upcoming Conferences

MONTREAL and CHARLOTTE, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced President and CEO, Joe Oliveto, will participate in one-on-one meetings...

MIST : 2.08 (+0.48%)
Milestone Pharmaceuticals: Q2 Earnings Snapshot

Milestone Pharmaceuticals: Q2 Earnings Snapshot

MIST : 2.08 (+0.48%)

Business Summary

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 2.31
2nd Resistance Point 2.23
1st Resistance Point 2.15
Last Price 2.08
1st Support Level 1.99
2nd Support Level 1.91
3rd Support Level 1.83

See More

52-Week High 3.06
Fibonacci 61.8% 2.13
Last Price 2.08
Fibonacci 50% 1.85
Fibonacci 38.2% 1.56
52-Week Low 0.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar